Clinical Response to Adalimumab: Relationship to Anti-Adalimumab Antibodies and Serum Adalimumab Concentrations in Rheumatoid Arthritis

Authors: Paul Peter TakLucien A AardenBen A C DijkmansWillem Frederik LemsMichael Tuahier NurmohamedSteven O StapelGerrit Jan J WolbinkCarla Ann WijbrandtsGeertje Margret Bartelds
Year: 2007
Times cited: 434

Key People For Adalimumab Antibodies

Top KOLs in the world
Paul *****
rheumatoid arthritis ankylosing spondylitis radiographic progression
Edward ***** ********
rheumatoid arthritis radiographic progression monoclonal antibodies
Piet * * * *** ****
rheumatoid arthritis disease activity score monoclonal antibodies
Rutgeerts *********
ulcerative colitis crohns disease mucosal healing
Josef ********* ******
rheumatoid arthritis systemic lupus erythematosus radiographic progression
Michael * *******
rheumatoid arthritis ankylosing spondylitis systemic lupus erythematosus

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis


BACKGROUND: A substantial proportion of patients with rheumatoid arthritis (RA) do not respond, or lose initial response, to adalimumab treatment. One explanation for non-response is that patients develop anti-adalimumab antibodies.

OBJECTIVES: To evaluate the incidence of formation of antibody against adalimumab and the association with serum adalimumab concentrations and clinical response.

METHODS: In a cohort of 121 consecutive patients with RA treated with adalimumab, serum adalimumab concentrations and antibodies against adalimumab were measured together with clinical response variables before and up to 28 weeks after the start of treatment.

RESULTS: Anti-adalimumab antibodies were detected in 21 patients (17%) during 28 weeks of treatment. EULAR non-responders had antibodies significantly more often than good responders (34% vs 5%; p = 0.032). Patients with antibodies showed less improvement in disease activity (mean (SD) delta DAS28 0.65 (1.35)) than patients without antibodies (mean delta DAS28 1.70 (1.35)) (p = 0.001). Patients with antibodies during follow-up had lower serum adalimumab concentrations at 28 weeks than patients without antibodies (median 1.2 mg/l, range 0.0-5.6 vs median 11.0 mg/l, range 2.0-33.0, respectively; p<0.001). Good responders had higher serum adalimumab concentrations than moderate responders (p = 0.021) and non-responders (p = 0.001). Concomitant methotrexate use was lower in the group with anti-adalimumab antibodies (52%) than in the group without antibodies (84%) (p = 0.003).

CONCLUSIONS: Serum antibodies against adalimumab are associated with lower serum adalimumab concentrations and non-response to adalimumab treatment.

to see all concepts, it's free!